|Contains||:||Esomeprazole Magnesium (40mg) + Domperidone 20mg|
|Category||:||Antacids, Anti-reflux Agents and Anti-ulcerants|
|Uses||:||Relief from Hyperacidity, Stomach ulcers, Zollinger-Ellison syndrome (ZES) or GERD|
Actipraz-DXR offers sustained release for sustained relief in Hyperacidity alleviating symptoms like difficulty in swallowing, burping and heartburn. Actipraz-DXR contains Esomeprazole magnesium which is helpful in the treatment of stomach and oesophagus problems like hyperacidity, acid reflux and ulcers. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs) which work by decreasing the amount of acid made in the stomach. It helps heal acid damage to the stomach and oesophagus and prevent ulcers. Actipraz-DXR also contains Domperidone which is helpful for relieving symptoms of nausea and vomiting. Domperidone works on the upper digestive tract increasing the movement of the intestines and stomach, enabling ease of food movement through the stomach.
Actipraz-DXR is manufactured by Invision Medi Sciences Pvt. Ltd., based in Bangalore, Karnataka. Invision is a leading pharmaceutical company providing truly world class healthcare solutions for more than a decade. It is known for its presence for delivering latest molecules in the market on a regular basis with a pan-India presence. The company offers a wide range of over 2500 products including Tablets, Capsules, Injections, Syringes, Lotions, Soaps, Syrups, Suspensions, Infusions, Sachets, Ointments, Eye/Ear Drops, Nasal drops, Powders etc. all DCGI approved products, prescribed by over 1 lakh doctors all over India.
You may have been prescribed Actipraz-DXR as you may be suffering from Hyperacidity, GERD, Stomach ulcers, Zollinger-Ellison (gastric acid hyper secretion) syndrome or Oesophageal ulcers.
Hyperacidity and GERD (Gastro-oesophageal Reflux Disease) are digestive diseases in which stomach acid or bile irritates the food pipe lining. Gastro-oesophageal reflux disease (GERD) is a severe form of acid reflux and is a chronic disease. It occurs when the LES (Lower oesophageal sphincter) is weak or relaxes inappropriately. This causes the return of the stomach’s contents back up into the oesophagus. Common signs and symptoms of Hyperacidity and GERD include a burning sensation in your chest (heartburn) usually after eating, chest pain, difficulty swallowing, a lump in the throat and regurgitation of food or sour liquid.
Stomach ulcers are sores on the lining of the stomach and small intestine. This occurs when the protective mucus lining of the stomach becomes ineffective. If the mucus layer is worn away and stops functioning efficiently, the acid can damage the stomach tissue, causing an ulcer.
Gastric and duodenal ulcers are also called as peptic ulcers. While gastric ulcers are open sores in the lining of the digestive tract, duodenal ulcers form in the lining of the duodenum, in the upper part of the small intestine.
Oesophageal ulcer is a painful sore which occurs when the layer of mucus which lines and protects the gastrointestinal tract wears away. This allows stomach acid and other gastric juices to irritate the gastrointestinal wall leading to ulceration. Oesophageal ulcers can also occur as a result of an infection from yeast and viruses. In Oesophageal ulcers, the burning pain in the chest can be severe and it may be accompanied with nausea, bloating, indigestion, lack of appetite, dry cough and a sour taste in the mouth.
Zollinger-Ellison syndrome (ZES) is a rare condition where tumours form in the duodenum or the pancreas. These tumours secrete large amounts of the hormone called as gastrin which causes excess acid production by the stomach. The additional acid produced results in peptic ulcers and can also cause diarrhoea and other symptoms.
Treatment for hyperacidity, acid reflux, stomach, duodenal and oesophageal ulcers may include medication such as antacids, H-2-receptor blockers and Proton pump inhibitors (PPIs). Dietary and lifestyle changes may be recommended to aid digestion. In severe cases, surgery may be advised to tighten the LES (lower oesophageal sphincter) valve or to insert a magnetic device to help the LES valve function.
As directed by your Physician
As directed by your Physician
Significant: Hypomagnesaemia, osteoporosis-related fractures, fundic gland polyps, subacute cutaneous lupus erythematosus, SLE, acute interstitial nephritis, atrophic gastritis, Clostridium difficile-associated diarrhoea, gastrointestinal infections (e.g. Salmonella, Campylobacter), vitamin B12 deficiency (long-term therapy). Blood and lymphatic system disorders: Rarely, leucopenia, thrombocytopenia. Eye disorders: Blurred vision. Gastrointestinal disorders: Flatulence, diarrhoea, nausea, abdominal pain, vomiting, constipation, xerostomia. General disorders and administration site conditions: Injection site reactions, fever, malaise. Hepatobiliary disorders: Increased liver enzymes.
Rarely, hepatitis. Immune system disorders: Rarely, hypersensitivity reactions (e.g. angioedema, anaphylactic shock, urticaria). Investigations: Altered thyroid hormone levels, increased gastrin, increased serum creatinine. Metabolism and nutrition disorders: Peripheral oedema. Rarely, hyponatraemia. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia, weakness. Nervous system disorders: Headache, dizziness, drowsiness, vertigo, paraesthesia. Psychiatric disorders: Insomnia, agitation, confusion, depression. Reproductive system and breast disorders: Very rarely, gynaecomastia. Respiratory, thoracic and mediastinal disorders: Cough, bronchospasm. Skin and subcutaneous tissue disorders: Pruritus, rash, dermatitis. Rarely, alopecia.
Patient with gastric malignancy, reduced body stores or risk factors for reduced vitamin B12 absorption, or those at risk of fractures and osteoporosis. Severe renal and hepatic impairment.
Children. Pregnancy and lactation. CYP2C19 ultrarapid metabolisers. Patient Counselling This drug may cause dizziness and blurred vision, if affected, do not drive or operate machinery. Monitoring Parameters Monitor serum Mg levels prior to treatment initiation and periodically thereafter. Assess for signs or symptoms of rebleeding, bone fractures, and Clostridium difficile-associated diarrhoea (CDAD).
Concomitant use with rilpivirine, atazanavir, and nelfinavir.
Increased risk of digoxin-induced cardiotoxic effects. May diminish the therapeutic effects of clopidogrel. Increased risk of hypomagnesaemia with diuretics. May increase serum concentrations of tacrolimus, methotrexate, cilostazol, and drugs metabolised by CYP2C19 (e.g. diazepam, citalopram, imipramine, phenytoin). May reduce absorption of ketoconazole, itraconazole, Fe salts, erlotinib. Concomitant use with warfarin may increase INR and prothrombin time. Esomeprazole serum levels may be decreased with CYP2C19 or CYP3A4 inducers (e.g. rifampicin) and increased with CYP3A4 inhibitors (e.g. voriconazole, clarithromycin). May prolong elimination half-life of cisapride.
Potentially Fatal: May substantially decrease the serum levels of atazanavir, nelfinavir, or rilpivirine which may lead to the development of drug resistance.
Symptoms: Weakness, confusion, headache, drowsiness, tachycardia, nausea, diaphoresis, flushing, dry mouth and other gastrointestinal symptoms. Management: Symptomatic and supportive treatment.
Intravenous: Store between 20-25°C. Protect from light and moisture. Oral: Store between 20-25°C. Protect from light and moisture.
Esomeprazole, the S-isomer of omeprazole, is a substituted benzimidazole proton pump inhibitor (PPI) that blocks the final step in gastric acid secretion by specific inhibition of H+/K+-ATPase enzyme system present on the secretory surface of the gastric parietal cells.